Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03930615
Recruitment Status : Recruiting
First Posted : April 29, 2019
Last Update Posted : July 16, 2020
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE April 26, 2019
First Posted Date  ICMJE April 29, 2019
Last Update Posted Date July 16, 2020
Actual Study Start Date  ICMJE June 21, 2019
Estimated Primary Completion Date August 8, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 26, 2019)
Percentage of participants with clinically-significant CMV infection from Week 14 (~100 days) post-transplant through Week 28 (~200 days) post-transplant [ Time Frame: From Week 14 (~100 day post-transplant) to Week 28 (up to ~200 days post-transplant) ]
The percentage of participants with clinically-significant CMV infection from Week 14 to Week 28 will be determined in each arm.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 26, 2019)
  • Percentage of participants experiencing ≥1 adverse events (AEs) [ Time Frame: Up to 24 weeks (from Week 14 post-transplant to Week 38 post-transplant) ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
  • Percentage of participants withdrawing from study drug due to an adverse event (AE) [ Time Frame: Up to 14 weeks (from Week 14 post-transplant to Week 28 post-transplant) ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
  • Percentage of participants with clinically significant CMV infection from Week 14 post-transplant through Week 38 post-transplant [ Time Frame: Up to 24 weeks (from Week 14 post-transplant to Week 38 post-transplant) ]
    The percentage of participants with clinically-significant CMV infection from Week 14 to Week 38 will be determined in each arm.
  • Percentage of participants with clinically significant CMV infection from Week 14 post-transplant through Week 48 post-transplant [ Time Frame: Up to 34 weeks (from Week 14 post-transplant to Week 48 post-transplant) ]
    The percentage of participants with clinically-significant CMV infection from Week 14 to Week 48 will be determined in each arm.
  • Time to onset of clinically significant CMV infection from Week 14 post-transplant to Week 28 post-transplant [ Time Frame: Up to 14 weeks (from Week 14 post-transplant to Week 28 post-transplant) ]
    The time to onset of clinically-significant CMV infection from Week 14 to Week 28 will be determined in each arm.
  • Time to onset of clinically significant CMV infection from Week 14 post-transplant to Week 48 post-transplant [ Time Frame: Up to 34 weeks (from Week 14 post-transplant to Week 48 post-transplant) ]
    The time to onset of clinically-significant CMV infection from Week 14 to Week 48 will be determined in each arm.
  • Percentage of participants with pre-emptive therapy (PET) for CMV viremia from Week 14 post-transplant to Week 28 post-transplant [ Time Frame: Up to 14 weeks (from Week 14 post-transplant to Week 28 post-transplant) ]
    The percentage of participants with PET for CMV viremia from Week 14 to Week 28 will be determined in each arm.
  • Percentage of participants with pre-emptive therapy (PET) for CMV viremia from Week 14 post-transplant to Week 48 post-transplant [ Time Frame: Up to 34 weeks (from Week 14 post-transplant to Week 48 post-transplant) ]
    The percentage of participants with PET for CMV viremia from Week 14 to Week 48 will be determined in each arm.
  • Percentage of participants with all-cause mortality from Week 14 post-transplant to Week 28 post-transplant [ Time Frame: Up to 14 weeks (from Week 14 post-transplant to Week 28 post-transplant) ]
    The percentage of participants with all-cause mortality from Week 14 to Week 28 will be determined.
  • Percentage of participants with all-cause mortality from Week 14 post-transplant to Week 48 post-transplant [ Time Frame: Up to 34 weeks (from Week 14 post-transplant to Week 48 post-transplant) ]
    The percentage of participants with all-cause mortality from Week 14 to Week 48 will be determined.
  • Time to all-cause mortality from Week 14 post-transplant to Week 28 post-transplant [ Time Frame: Up to 14 weeks (from Week 14 post-transplant to Week 28 post-transplant) ]
    The time to all-cause mortality from Week 14 to Week 28 will be determined.
  • Time to all-cause mortality from Week 14 post-transplant to Week 48 post-transplant [ Time Frame: Up to 34 weeks (from Week 14 post-transplant to Week 48 post-transplant) ]
    The time to all-cause mortality from Week 14 to Week 48 will be determined.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Official Title  ICMJE A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)
Brief Summary The purpose of this study is to evaluate the safety and efficacy of letermovir (LET) versus placebo when extended from 100 days to 200 days post-transplant in cytomegalovirus (CMV) seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It is hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Cytomegalovirus Infection
Intervention  ICMJE
  • Drug: Letermovir
    LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
    Other Name: PREVYMIS™, MK-8228
  • Drug: Placebo
    Placebo was administered as tablets matched to LET or as inactive (saline) intravenous infusion.
Study Arms  ICMJE
  • Experimental: Letermovir
    Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of LET (480 mg once daily alone or 240 mg once daily for participants on cyclosporin A) treatment.
    Intervention: Drug: Letermovir
  • Placebo Comparator: Placebo
    Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of placebo treatment.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 26, 2019)
216
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 27, 2021
Estimated Primary Completion Date August 8, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • have documented positive CMV serostatus (CMV immunoglobulin G [IgG] seropositive) for recipient (R+) at the time of transplant
  • has a history of allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord blood transplant) within ~100 days prior to randomization
  • has undetectable CMV deoxyribonucleic acid (DNA) or detectable/not quantifiable CMV DNA from a plasma sample collected within 14 days prior to randomization
  • has received LET as primary prophylaxis that started within 28 days of HSCT and continued through Week 14 post-transplant (± 1 week) prior to randomization
  • is at high risk of CMV disease, defined as meeting one or more of the following criteria:
  • has a related donor with at least 1 mismatch at 1 of the specified 3 human leukocyte antigen (HLA) gene loci (HLA-A, B, or DR)
  • has an unrelated donor with at least one mismatch at one of the specified four HLA gene loci (HLA-A, B, C, and DRB1)
  • has a haploidentical donor
  • has umbilical cord blood as the stem-cell source
  • has ex-vivo T-cell-depleted grafts
  • has received anti-thymocyte globulin
  • has received alemtuzumab
  • has graft versus host disease (GVHD) or other conditions, requiring the use of systemic prednisone (or equivalent) at a dose of ≥1 mg/kg of body weight per day within 6 weeks of randomization
  • for female participants, is not pregnant or breastfeeding, and is either not a woman of childbearing potential (WOCBP) or is a WOBCP who agrees to use acceptable contraception during the treatment period and for ≥28 days after the last dose of study drug.

Exclusion Criteria:

  • has a history of CMV end-organ disease or preemptive treatment therapy for CMV after HSCT prior to randomization
  • has a history of >14 days total of LET interruption during the first 100 days post-transplant prior to randomization
  • has suspected or known hypersensitivity to active or inactive ingredients of LET formulations
  • has severe hepatic insufficiency defined as Child-Pugh Class C within 14 days prior to randomization.
  • has serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5× the upper limit of normal (ULN) within 14 days prior to randomization
  • has end-stage renal impairment with a creatinine clearance less than 10 mL/min, as calculated by the Cockcroft-Gault equation using serum creatinine within 14 days prior to randomization
  • has both moderate hepatic insufficiency AND moderate-to-severe renal insufficiency
  • has an uncontrolled infection on the day of enrollment
  • requires mechanical ventilation or is hemodynamically unstable at the time of enrollment
  • has a documented positive result for a human immunodeficiency virus antibody (HIV-Ab) test at any time prior to screening, or for hepatitis C virus antibody (HCV-Ab) with detectable HCV ribonucleic acid (RNA), or hepatitis B surface antigen (HBsAg) within 6 months prior to screening.
  • has active solid tumor malignancies with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (eg, lymphomas)
  • has received any prohibited medications within 7 days prior to screening
  • has received cidofovir or CMV immunoglobulin with 30 days prior to screening
  • is currently participating or has participated in a study with an unapproved investigational compound, monoclonal antibody, or device within 28 days or 5× half-life of the investigational compound or monoclonal antibody, whichever is longer, of initial dosing in this study
  • has previously participated in this study or any other study involving LET, or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study
  • is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 28 days after the last dose of study therapy
  • is expecting to donate eggs starting from the time of consent through 28 days after the last dose of study therapy
  • has clinically relevant drug or alcohol abuse within 12 months of screening that may interfere with participant treatment, assessment, or compliance with the protocol as assessed by the investigator
  • has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or would be put at undue risk as judged by the investigator, such that it is not in the best interest of the participant to participate in this study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com
Listed Location Countries  ICMJE France,   Germany,   Italy,   Japan,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03930615
Other Study ID Numbers  ICMJE 8228-040
2018-001038-17 ( EudraCT Number )
MK-8228-040 ( Other Identifier: Merck Sharp & Dohme Corp. )
194797 ( Registry Identifier: JAPIC-CTI )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme Corp.
PRS Account Merck Sharp & Dohme Corp.
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP